Method and kit for quantifying lipoprotein cholesterol
By employing peroxidase to transfer non-target lipoprotein cholesterol and quantifying HDL cholesterol in two steps, the method stabilizes measurements and improves linearity in diluted samples, addressing the challenge of inaccurate cholesterol quantification.
Patent Information
- Application Number
- JP2023111157
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-07-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2038-08-08
AI Technical Summary
Existing methods for quantifying lipoprotein cholesterol in test samples face challenges in maintaining accurate measurement values when the samples are diluted, leading to a decrease in measured cholesterol levels due to interference from hydrogen peroxide generated from non-target components.
The method involves using peroxidase in the first step to transfer non-target lipoprotein cholesterol outside the reaction system and quantifying the remaining HDL cholesterol in the second step, with specific concentrations of peroxidase and dilution ratios to stabilize measurements.
This approach suppresses the decrease in measured lipoprotein cholesterol values and improves the linearity of the calibration curve, ensuring stable quantification even in diluted samples.
Smart Images

Figure 0007579919000013 
Figure 0007579919000014 
Figure 0007579919000015
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for quantitatively determining lipoprotein cholesterol in a test sample, which improves a decrease in the measured value of lipoprotein cholesterol, and a quantitative determination kit used in this method. [Background technology]
[0002] In the field of clinical testing, a method is widely used in which hydrogen peroxide is generated from the component to be measured, and the concentration of the component to be measured in a sample is measured by quantifying the amount of hydrogen peroxide. In such a method, hydrogen peroxide generated from substances other than the component to be measured causes an error in the measurement value, so that the hydrogen peroxide generated from substances other than the component to be measured is generally eliminated by a method of decomposing the hydrogen peroxide generated from the substance other than the component to be measured by the action of catalase into water and oxygen, or by a method of reacting the hydrogen peroxide with a phenolic or aniline hydrogen donor compound using peroxidase to convert it into a colorless quinone. For example, a system for eliminating endogenous free glycerol is used in a reagent for measuring neutral fat, a system for eliminating creatine and sarcosine is used in a reagent for measuring creatinine, and a system for eliminating lipoprotein cholesterol other than the target component is used in a reagent for measuring HDL-cholesterol or LDL-cholesterol. Of these, the catalase-based elimination system is often used, but it may be interfered with by the presence of components that inhibit catalase in the sample.
[0003] When catalase is used in a method for quantifying cholesterol in lipoproteins, it is generally used in the first step (step (1)) of transferring cholesterol in lipoproteins other than the target lipoprotein in the test sample out of the reaction system. That is, in step (1), cholesterol oxidase and cholesterol esterase are allowed to act on cholesterol contained in lipoproteins other than the target lipoprotein, and the generated hydrogen peroxide is removed by catalase.
[0004] In the subsequent second step (step (2)), cholesterol oxidase and cholesterol esterase are allowed to act on the cholesterol remaining in the lipoprotein to be measured that was not eliminated in step (1), and the hydrogen peroxide produced is converted to a quinone dye by the peroxidase, a hydrogen donor, and a hydrogen acceptor. The amount of cholesterol in the lipoprotein to be measured is quantified by measuring the absorbance of the quinone dye. In this case, in order to inhibit the action of catalase present from step (1), a catalase inhibitor such as sodium azide is added in step (2) to inhibit catalase. However, before catalase is completely inhibited, some of the hydrogen peroxide derived from cholesterol in the lipoprotein to be measured, which is generated in step (2), may be removed.
[0005] The partial removal of hydrogen peroxide by catalase does not have a significant effect on the measured cholesterol value in normal measurements. However, in the past, when the measured value was significantly outside the appropriate measurable range or was adversely affected by substances in the test sample, the test sample was diluted and the cholesterol measured value was measured in a low range. In such cases, the effect of the partial removal of hydrogen peroxide by catalase was large, causing the cholesterol measured value itself to decrease, which was the cause of inaccurate measurement.
[0006] On the other hand, as a method for quantifying cholesterol in lipoproteins using the first and second steps, Patent Document 1 discloses a method in which lipoproteins other than HDL are eliminated with catalase in the first step, and HDL is measured using a surfactant that acts specifically on HDL in the second step. Patent Document 2 discloses a method in which cholesterol in lipoproteins other than small, dense LDL is eliminated using a surfactant that acts on substances other than small, dense LDL in the first step, and then the cholesterol in the remaining small, dense LDL is quantified. Furthermore, Patent Document 3 discloses a method for measuring triglyceride-rich lipoproteins (TRL), in which cholesterol in lipoproteins other than TRL is eliminated using a surfactant that acts on substances other than TRL, and then the cholesterol in the remaining TRL is quantified. However, neither of the patent documents discloses a method for suppressing a decrease in the measured value of lipoprotein cholesterol in a diluted sample. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] WO98 / 26090 publication [Patent Document 2] JP 2013-148589 A [Patent Document 3] JP 2017-209035 A Summary of the Invention [Problem to be solved by the invention]
[0008] The object of the present invention is to provide a method for quantifying lipoprotein cholesterol in a test sample, which suppresses a decrease in the measured value of lipoprotein cholesterol even when the test sample is diluted, and improves the linearity of the calibration curve at low measured values of cholesterol, and a quantification kit for use in this method. [Means for solving the problem]
[0009] As a result of extensive research, the inventors of the present application discovered that the use of peroxidase improves the reduction in the measured value of lipoprotein cholesterol even when the test sample is diluted, and improves the linearity of the calibration curve at low measured values of cholesterol, compared to methods using catalase, and thus completed the present invention.
[0010] That is, the present invention is as follows. [1] A method for quantifying HDL cholesterol, comprising a first step of transferring lipoprotein cholesterol other than HDL cholesterol in a diluted test sample out of a reaction system, and a second step of quantifying HDL cholesterol remaining in the reaction system, The concentration of HDL cholesterol in the diluted test sample subjected to the first step is 19.1 mg / dL or less; A method for suppressing a decrease in the measured value of HDL cholesterol by making 1.2 U / mL or more of peroxidase present in the first step. [2] The method for quantifying described in [1], wherein the dilution ratio is 2 to 40 times. [3] The method according to [1] or [2], wherein 1.2 to 50.0 U / mL of peroxidase is present in the first step. The method according to [1] or [2], wherein 0.5 to 50.0 U / mL of peroxidase is present in the first step. [4] The method according to any one of [1] to [3], wherein the concentration of HDL cholesterol in the diluted test sample subjected to the first step is 2.2 to 7.8 mg / dL. [5] A quantitative kit for HDL cholesterol used in any of the methods of [1] to [4], comprising a first reagent for transferring lipoprotein cholesterol other than HDL cholesterol out of the reaction system, and a second reagent for quantifying HDL cholesterol remaining in the reaction system, the first reagent comprising 1.2 U / mL or more of peroxidase. Effect of the Invention
[0011] According to the present invention, even when a test sample is diluted, a decrease in the measured value of lipoprotein cholesterol is suppressed, and the linearity of the calibration curve at low measured values of cholesterol is improved, thereby providing a method for stably quantifying lipoprotein cholesterol, and a quantification kit for use in this method. [Brief description of the drawings]
[0012] [Figure 1] FIG. 13 is a diagram showing the results of evaluating linearity when the HDL cholesterol concentration in a sample was measured using a combination of Reagent A and Reagent E (Comparative Example 4). [Diagram 2] FIG. 13 is a diagram showing the results of evaluating linearity when the HDL cholesterol concentration in a sample is measured using a combination of Reagent B and Reagent F (Example 10). [Diagram 3] FIG. 13 shows the results of evaluating linearity when the HDL cholesterol concentration in a sample was measured using a combination of Reagent C and Reagent F (Example 11). [Figure 4] FIG. 13 shows the results of evaluating linearity when the HDL cholesterol concentration in a sample was measured using a combination of Reagent D and Reagent F (Example 12). [Diagram 5] FIG. 13 is a diagram showing the results of evaluating linearity when the LDL cholesterol concentration in a sample is measured using a combination of Reagent G and Reagent K (Comparative Example 5). [Figure 6] FIG. 13 is a diagram showing the results of evaluating linearity when the LDL cholesterol concentration in a sample is measured using a combination of Reagent H and Reagent L (Example 13). [Figure 7] FIG. 13 is a diagram showing the results of evaluating linearity when the LDL cholesterol concentration in a sample is measured using a combination of Reagent I and Reagent L (Example 14). [Figure 8] FIG. 13 is a diagram showing the results of evaluating linearity when the LDL cholesterol concentration in a sample is measured using a combination of Reagent J and Reagent L (Example 15). [Figure 9]FIG. 13 is a diagram showing the results of evaluating linearity when the sdLDL cholesterol concentration in a sample is measured using a combination of Reagent M and Reagent Q (Comparative Example 6). [Figure 10] FIG. 13 is a diagram showing the results of evaluating linearity when the sdLDL cholesterol concentration in a sample is measured using a combination of Reagent N and Reagent R (Example 16). [Figure 11] FIG. 13 is a diagram showing the results of evaluating linearity when the sdLDL cholesterol concentration in a sample is measured using a combination of reagent O and reagent R (Example 17). [Figure 12] FIG. 13 is a diagram showing the results of evaluating linearity when the sdLDL cholesterol concentration in a sample is measured using a combination of Reagent P and Reagent R (Example 18). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The present invention is characterized in that in a method for quantifying lipoprotein cholesterol in a test sample, a decrease in the measured value of lipoprotein cholesterol is improved by adding peroxidase to a diluted specimen obtained by diluting the test sample.
[0014] The cholesterol contained in lipoproteins is esterified cholesterol (cholesterol In the present invention, the term "cholesterol" is used simply to refer to "cholesterol esters" and "free cholesterol." In the present invention, a low measurement value of cholesterol in a diluted specimen obtained by diluting a test sample is usually 70.0 mg / dL or less, and more preferably in the range of 0.1 to 50 mg / dL, and particularly preferably 0.5 to 40 mg / dL.
[0015] The cholesterol-containing lipoproteins to be quantified by the method of the present invention are classified by electrophoresis or ultracentrifugation, and include chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL), small, dense LDL, high density lipoproteins (HDL), etc. The combined density of chylomicrons (including chylomicron remnants), VLDL (including VLDL remnants), and IDL is 1.019 g / cm. 3 Also included are triglyceride-rich lipoproteins (TRL) of less than 100 mg / kg.
[0016] The test sample in the present invention is not particularly limited as long as it contains lipoprotein and cholesterol in the lipoprotein is to be quantified, but is usually a body fluid such as blood (including whole blood, serum and plasma). In the present invention, lipoprotein cholesterol is measured using a diluted specimen obtained by diluting the test sample with a diluent such as physiological saline.
[0017] The method for quantifying lipoprotein cholesterol according to the present invention may employ any method well known in the art, except for adding peroxidase to a diluted sample. For example, a method may be used in which cholesterol oxidase and cholesterol esterase are allowed to act on cholesterol using a quantitative reagent, the hydrogen peroxide produced is converted to a quinone dye by the action of peroxidase, a hydrogen donor, and a hydrogen acceptor, and the dye is then quantitatively measured by absorbance measurement. In the present invention, the amount of peroxidase added is usually 0.1 to 100.0 U / mL, preferably 0.5 to 50.0 U / mL, and more preferably 1.0 to 30.0 U / mL.
[0018] In the present invention, the method of the present invention includes a first step (step (1)) of selectively eliminating cholesterol from lipoproteins not to be measured in a test sample by transferring them out of the reaction system, and a second step (step (2)) of quantifying cholesterol in the target lipoproteins remaining in the reaction system, thereby making it possible to more accurately quantify cholesterol in the target lipoproteins.
[0019] In the present invention, when the term "react" is used with respect to lipoprotein, it means that the structure of the lipoprotein is changed by a surfactant or an enzyme, so that the enzyme can more easily act on the cholesterol inside.
[0020] In step (1) of the present invention, cholesterol in lipoproteins other than the measurement target is selectively eliminated. Here, "elimination" means decomposing cholesterol and making the decomposition product not detectable in the next step (2). As a method for selectively eliminating cholesterol contained in lipoproteins other than the measurement target, a method of acting cholesterol oxidase or a specific cholesterol esterase on a test sample and removing the generated hydrogen peroxide can be mentioned. In step (1) of the present invention, peroxidase is added to a diluted specimen obtained by diluting the test sample. Hydrogen peroxide can be converted to colorless quinone by using a hydrogen donor compound that reacts with hydrogen peroxide by the action of peroxidase to generate colorless quinone. The amount of peroxidase added in step (1) is usually 0.1 to 100.0 U / mL, preferably 0.5 to 50.0 U / mL, and more preferably 1.0 to 30.0 U / mL.
[0021] The method of selectively eliminating cholesterol in a specific lipoprotein in the first step is widely adopted in methods for quantifying LDL cholesterol (e.g., WO98 / 47005, etc.) and HDL cholesterol (e.g., WO98 / 26090, etc.) and is well known. Step (1) of the present invention can also be carried out by these well-known methods.
[0022] In the next step (2), the cholesterol remaining in the lipoprotein to be measured without being eliminated in the step (1) is enzymatically quantified. The enzymatic quantification method of cholesterol is well known in the art, and includes, for example, a method in which cholesterol is reacted with cholesterol oxidase and cholesterol esterase, the hydrogen peroxide produced is converted to a quinone dye by peroxidase, a hydrogen donor, and a hydrogen acceptor, and the dye is quantified by measuring the absorbance. When cholesterol oxidase and cholesterol esterase are used in the step (1), the cholesterol oxidase and cholesterol esterase used in the step (1) can be used as they are in the step (2), and there is no need to add them anew.
[0023] At least one surfactant can be used in step (1) and step (2) of the present invention. The use of a suitable surfactant can promote the enzymatic reaction in each step.
[0024] The cholesterol oxidase that can be used in the present invention is not particularly limited as long as it is an enzyme that can oxidize cholesterol to generate hydrogen peroxide, and can be, for example, cholesterol oxidase derived from animals or microorganisms. These may be produced by genetic engineering, and may or may not be chemically modified. In addition, the cholesterol esterase that can be used in the present invention is not particularly limited as long as it acts on esterified cholesterol.
[0025] The amount of each of the enzymes, cholesterol esterase and cholesterol oxidase, used in the present invention is not particularly limited and can be appropriately set, but is usually 0.001 U to 2000 U / mL, preferably 0.1 to 1000 U / mL.
[0026] The hydrogen donor used in the present invention is preferably an aniline derivative, and examples of the aniline derivative include N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline (TOOS), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), N-ethyl-N-(3-sulfopropyl)-3-methylaniline (TOPS), N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HDAOS), N-(3-sulfopropyl)aniline (HALPS), and N-(3-sulfopropyl)-3-methoxy-5-aniline (HMMPS).
[0027] As the hydrogen acceptor, 4-aminoantipyrine, methylbenzothiazolone hydrazone, or the like can be used.
[0028] As the reaction solution, various buffer solutions used in ordinary biochemical reactions can be used, and the pH of the buffer solution is preferably between 5 and 8. The solution is preferably a Good's, Tris, phosphate, or glycine buffer solution, and Good's buffer solutions such as bis(2-hydroxyethyl)iminotris(hydroxyethyl)methane (Bis-Tris), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), piperazine-1,4-bis(2-ethanesulfonic acid), 1.5 sodium salt, monohydrate (PIPES1.5Na), 2-hydroxy-3-morpholinopropanesulfonic acid (MOPSO), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES), and piperazine-1,4-bis(2-hydroxy-3-propanesulfonic acid) (POPSO) are preferred.
[0029] Each step in the present invention is preferably carried out at a pH of 5 to 10, and more preferably at a pH of 6 to 8.
[0030] The reaction temperature in each step is preferably 20° C. to 45° C., more preferably 25° C. to 40° C. The reaction time in each step is preferably 1 to 10 minutes, more preferably 3 to 7 minutes.
[0031] In carrying out the quantitative determination method of the present invention, the reagent used may be divided into a plurality of reagent compositions. In the present invention, at least two types of reagent compositions are prepared, namely, a reagent composition (first reagent) for carrying out the first step (i.e., step (1)) of eliminating cholesterol in lipoproteins other than the lipoprotein to be measured, and a reagent composition (second reagent) for carrying out the step (i.e., step (2)) of measuring cholesterol in the lipoprotein to be measured, and a combination of these two types of reagent compositions can be used as a quantitative determination kit for lipoprotein cholesterol.
[0032] The reagent composition (first reagent) for carrying out step (1) contains peroxidase that scavenges hydrogen peroxide. The content of peroxidase in the first reagent is usually 0.1 to 100.0 U / mL, preferably 0.5 to 50.0 U / mL, and more preferably 1.0 to 30.0 U / mL. The reagent composition (first reagent) may further contain a hydrogen donor such as cholesterol oxidase, cholesterol esterase, or an aniline derivative, a surfactant suitable for scavengers cholesterol in lipoproteins other than the lipoprotein to be quantified, and the like.
[0033] The reagent composition (second reagent) for carrying out step (2) may contain a surfactant that reacts with all lipoproteins. The reagent composition (second reagent) may further contain a hydrogen acceptor such as 4-aminoantipyrine, peroxidase, etc.
[0034] The reagent composition for carrying out step (1) (first reagent) and the reagent composition for carrying out step (2) (second reagent) may contain monovalent cations (e.g., monovalent metal ions), divalent cations (e.g., divalent metal ions) or salts thereof, polyanions (e.g., heparin, dextran sulfate, phosphotungstate), and serum albumin, as necessary. The pH of each reagent composition is near neutral, for example, pH 5 to pH 9, and preferably pH 6 to pH 8, and the pH may be adjusted by adding a buffer solution.
[0035] To quantify cholesterol in lipoproteins to be measured by the method of the present invention, a reagent composition for carrying out step (1) (first reagent) is added to a diluted specimen obtained by diluting a test sample, the diluted specimen is reacted, and then a reagent composition for carrying out step (2) (second reagent) is added and reacted, and the absorbance is measured. EXAMPLES
[0036] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the following examples.
[0037] Examples 1 to 3, Comparative Example 1 The reagent composition used in the first step was designated the first reagent, and the reagent composition used in the second step was designated the second reagent. Reagents A to D were prepared as the first reagents, and reagents E to F were prepared as the second reagents, so as to have the following compositions.
[0038] Reagent A Good's buffer solution (pH 6.6) 100mmol / L TOOS 1.5mmol / L Catalase 600U / mL Cholesterol esterase 1.4U / mL Cholesterol oxidase 0.8U / mL Polyoxyethylene-polyoxypropylene condensate 0.25g / L
[0039] Reagent B Good's buffer solution (pH 6.6) 100mmol / L TOOS 1.5mmol / L Peroxidase 1.2U / mL Cholesterol esterase 1.4U / mL Cholesterol oxidase 0.8U / mL Polyoxyethylene-polyoxypropylene condensate 0.25g / L
[0040] Reagent C Good's buffer solution (pH 6.6) 100mmol / L TOOS 1.5mmol / L Peroxidase 6.5U / mL Cholesterol esterase 1.4U / mL Cholesterol oxidase 0.8U / mL Polyoxyethylene-polyoxypropylene condensate 0.25g / L
[0041] Reagent D Good's buffer solution (pH 6.6) 100mmol / L TOOS 1.5mmol / L Peroxidase 20.0U / mL Cholesterol esterase 1.4U / mL Cholesterol oxidase 0.8U / mL Polyoxyethylene-polyoxypropylene condensate 0.25g / L
[0042] Reagent E Good's buffer solution (pH 7.0) 100mmol / L Sodium azide 0.1% 4-Aminoantipyrine 4.0mmol / L Peroxidase 3.5U / mL Polyoxyethylene tribenzyl phenyl ether 14g / L
[0043] Reagent F Good's buffer solution (pH 7.0) 100mmol / L 4-Aminoantipyrine 4.0mmol / L Polyoxyethylene tribenzyl phenyl ether 14g / L
[0044] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a secondary wavelength of 700 nm was measured, and the HDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve.
[0045] The samples were prepared as follows: undiluted HDL high-concentration specimen (dilution ratio 1x), and five types of samples were prepared by diluting the HDL high-concentration specimen with physiological saline 2x, 10x, 20x, and 40x. The HDL cholesterol concentration in each sample was measured, and the measured value (mg / dL) was multiplied by the dilution ratio to obtain the undiluted equivalent value (mg / dL). Tables 1 to 4 show the undiluted equivalent value at each dilution ratio as a percentage of the theoretical value, assuming that the measured value of the undiluted solution is the theoretical value.
[0046] Compared to the combination of Reagent A and Reagent E (Table 1: Comparative Example 1), which uses catalase in the first step and peroxidase in the second step, the combinations of Reagent B and Reagent F (Table 2: Example 1), Reagent C and Reagent F (Table 3: Example 2), and Reagent D and Reagent F (Table 4: Example 3), which use peroxidase in the first step, showed improved reduction in measurement values due to the effects of dilution, confirming that the accuracy of measurement values when the sample was diluted was improved.
[0047] [Table 1]
[0048] [Table 2]
[0049] [Table 3]
[0050] [Table 4]
[0051] Examples 4 to 6, Comparative Example 2 The reagent composition used in the first step was designated the first reagent, and the reagent composition used in the second step was designated the second reagent. Reagents G to J as the first reagents and K to L as the second reagents were prepared to have the following compositions.
[0052] Reagent G Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Catalase 1200U / mL Cholesterol esterase 0.6U / mL Cholesterol oxidase 0.5U / mL Polyoxyethylene tribenzyl phenyl ether 2.7g / L Polyoxyethylene distyrenated phenyl ether 0.3g / L
[0053] Reagent H Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 0.5U / mL Cholesterol esterase 0.6U / mL Cholesterol oxidase 0.5U / mL Polyoxyethylene tribenzyl phenyl ether 2.7g / L Polyoxyethylene distyrenated phenyl ether 0.3g / L
[0054] Reagent I Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 1.7U / mL Cholesterol esterase 0.6U / mL Cholesterol oxidase 0.5U / mL Polyoxyethylene tribenzyl phenyl ether 2.7g / L Polyoxyethylene distyrenated phenyl ether 0.3g / L
[0055] Reagent J Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 3.5U / mL Cholesterol esterase 0.6U / mL Cholesterol oxidase 0.5U / mL Polyoxyethylene tribenzyl phenyl ether 2.7g / L Polyoxyethylene distyrenated phenyl ether 0.3g / L
[0056] Reagent K Good's buffer solution (pH 7.0) 100mmol / L Sodium azide 0.1% 4-Aminoantipyrine 4.0mmol / L Peroxidase 5.0U / mL Polyoxyethylene alkyl ether 6g / L
[0057] Reagent L Good's buffer solution (pH 7.0) 100mmol / L 4-Aminoantipyrine 4.0mmol / L Polyoxyethylene alkyl ether 6g / L
[0058] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a secondary wavelength of 700 nm was measured, and the LDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve. The samples were prepared as follows: a stock solution of the high-concentration LDL specimen (dilution ratio 1x), and five types of samples in which the high-concentration LDL specimen was diluted 2x, 10x, 20x, and 40x with physiological saline. The LDL cholesterol concentration in each sample was measured, and the obtained measured value (mg / dL) was multiplied by the dilution ratio to obtain the stock solution equivalent value (mg / dL). Tables 5 to 8 show the stock solution equivalent value of each dilution ratio as a percentage of the theoretical value, assuming that the measured value of the stock solution is the theoretical value.
[0059] Compared to the combination of Reagent G and Reagent K (Table 5: Comparative Example 2), which uses catalase in the first step and peroxidase in the second step, the combinations of Reagent H and Reagent L (Table 6: Example 4), Reagent I and Reagent L (Table 7: Example 5), and Reagent J and Reagent L (Table 8: Example 6), which use peroxidase in the first step, showed improved reduction in measurement values due to the effects of dilution, confirming that the accuracy of measurement values when the sample was diluted was improved.
[0060] [Table 5]
[0061] [Table 6]
[0062] [Table 7]
[0063] [Table 8]
[0064] Examples 7 to 9, Comparative Example 3 The reagent composition used in the first step was designated the first reagent, and the reagent composition used in the second step was designated the second reagent. Reagents M to P as the first reagents and reagents Q to R as the second reagents were prepared to have the following compositions.
[0065] Reagent M Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Catalase 1200U / mL Cholesterol esterase 1.6U / mL Cholesterol oxidase 0.6U / mL Sphingomyelinase 2.70U / mL Polyoxyethylene tribenzyl phenyl ether 0.68g / L Polyoxyethylene distyrenated phenyl ether 1.20g / L
[0066] Reagent N Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 0.5U / mL Cholesterol esterase 1.6U / mL Cholesterol oxidase 0.6U / mL Sphingomyelinase 2.70U / mL Polyoxyethylene tribenzyl phenyl ether 0.68g / L Polyoxyethylene distyrenated phenyl ether 1.20g / L
[0067] Reagent O Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 1.7U / mL Cholesterol esterase 1.6U / mL Cholesterol oxidase 0.6U / mL Sphingomyelinase 2.70U / mL Polyoxyethylene tribenzyl phenyl ether 0.68g / L Polyoxyethylene distyrenated phenyl ether 1.20g / L
[0068] Reagent P Good's buffer solution (pH 7.0) 100mmol / L TOOS 2.0mmol / L Peroxidase 3.5U / mL Cholesterol esterase 1.6U / mL Cholesterol oxidase 0.6U / mL Sphingomyelinase 2.70U / mL Polyoxyethylene tribenzyl phenyl ether 0.68g / L Polyoxyethylene distyrenated phenyl ether 1.20g / L
[0069] Reagent Q Good's buffer solution (pH 7.0) 100mmol / L Sodium azide 0.1% 4-Aminoantipyrine 4.0mmol / L Peroxidase 5.0U / mL Polyoxyethylene alkyl ether 6g / L
[0070] Reagent R Good's buffer solution (pH 7.0) 100mmol / L 4-Aminoantipyrine 4.0mmol / L Polyoxyethylene alkyl ether 6g / L
[0071] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a sub wavelength of 700 nm was measured, and the sdLDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve. The samples were prepared as follows: undiluted sdLDL high-concentration specimen (dilution ratio 1x), and five types of samples were prepared by diluting the sdLDL high-concentration specimen with physiological saline 2x, 10x, 20x, and 40x. The sdLDL cholesterol concentration in each sample was measured, and the measured value (mg / dL) was multiplied by the dilution ratio to obtain the undiluted equivalent value (mg / dL). Tables 9 to 12 show the undiluted equivalent value at each dilution ratio as a percentage of the theoretical value, assuming that the measured value of the undiluted solution is the theoretical value.
[0072] Compared to the combination of Reagent M and Reagent Q (Table 9: Comparative Example 3), which uses catalase in the first step and peroxidase in the second step, the combinations of Reagent N and Reagent R (Table 10: Example 7), Reagent O and Reagent R (Table 11: Example 8), and Reagent P and Reagent R (Table 12: Example 9), which use peroxidase in the first step, showed improved reduction in measurement values due to the effects of dilution, confirming that the accuracy of measurement values when the sample was diluted was improved.
[0073] [Table 9]
[0074] [Table 10]
[0075] [Table 11]
[0076] [Table 12]
[0077] Examples 10 to 12, Comparative Example 4 The reagent composition used in the first step was designated as the first reagent, and the reagent composition used in the second step was designated as the second reagent. Linearity was evaluated using the above reagents A to D as the first reagent and the above reagents E to F as the second reagent.
[0078] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a secondary wavelength of 700 nm was measured, and the HDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve. A sample with a high HDL concentration was diluted in 10 steps so that the ratio of the sample to physiological saline was 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0, and the measured values were evaluated for linearity in accordance with the CLSI guideline EP-06A. The results for the combination of Reagent A and Reagent E (Comparative Example 4), the combination of Reagent B and Reagent F (Example 10), the combination of Reagent C and Reagent F (Example 11), and the combination of Reagent D and Reagent F (Example 12) are shown in Figures 1, 2, 3, and 4, respectively.
[0079] In the CLSI guideline EP-06A, polynomial regression analysis is performed on the dilution level and the measured value, and the polynomial regression fit that best fits the relationship between the dilution level and the measured value is statistically selected and used to evaluate linearity. In the selection of polynomial regression, a significance test is performed between the linear regression fit and the quadratic or cubic regression fit of the polynomial regression. If there is no significant difference between the linear regression and both the quadratic and cubic regression fits, the linear regression is selected. If there is a significant difference between the linear regression and either the quadratic or cubic regression fits, the polynomial regression with the significant difference is selected, and if there is a significant difference between the linear regression and both the quadratic and cubic regression fits, the polynomial regression fit with the smallest standard error is selected. In the figure, Linear fit is the linear regression fit, Nonlinear fit is the selected quadratic or cubic regression fit, and Difference plot of nonlinearity is the difference between the linear regression fit and the selected polynomial regression fit. If linear regression is selected for the regression analysis of dilution levels and measured values, the relationship between dilution levels and measured values is deemed to be linear at that point. If polynomial regression is selected, linearity is evaluated using the difference plot of nonlinearity, and the closer the difference plot of nonlinearity value is to zero at all dilution levels, the more linear the relationship between dilution levels and measured values is deemed to be.
[0080] In Fig. 1 (Comparative Example 4), the values of the difference plot of nonlinearity are far from zero both above and below, indicating that the straight line is distorted. On the other hand, in Fig. 2 (Example 10) and Fig. 3 (Example 11), linear regression is selected, and the relationship between the dilution level and the measured value is determined to be linear. In Fig. 4 (Example 12), polynomial regression is selected, but compared to Fig. 1, the values of the difference plot of nonlinearity converge to zero, and it can be seen that the distortion of the straight line in the low value range, particularly for dilution levels 1 to 5, has been improved.
[0081] Therefore, compared to the combination of reagents A and E (Figure 1: Comparative Example 4), which used catalase in the first step and peroxidase in the second step, it was confirmed that the linearity was improved in the combinations of reagents B and F (Figure 2: Example 10), reagents C and F (Figure 3: Example 11), and reagents D and F (Figure 4: Example 12), which used peroxidase in the first step.
[0082] Examples 13 to 15, Comparative Example 5 The reagent composition used in the first step was designated the first reagent, and the reagent composition used in the second step was designated the second reagent. Linearity was evaluated using the above reagents G to J as the first reagent and the above reagents K to L as the second reagent.
[0083] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a secondary wavelength of 700 nm was measured, and the LDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve. A sample with a high LDL concentration was diluted in 10 steps so that the ratio of the sample to physiological saline was 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0, and the linearity of the obtained measured values was evaluated in accordance with the CLSI guideline EP-06A in the same manner as in Examples 10 to 12 and Comparative Example 4. The results of the combination of Reagent G and Reagent K (Comparative Example 5), the combination of Reagent H and Reagent L (Example 13), the combination of Reagent I and Reagent L (Example 14), and the combination of Reagent J and Reagent L (Example 15) are shown in Figures 5, 6, 7, and 8, respectively. In Figure 5 (Comparative Example 5), the difference plot of nonlinearity values at each dilution level are significantly different above and below zero, and the straight line is significantly distorted. On the other hand, in Figures 6 (Example 13) to 8 (Example 15), linear regression was selected for the difference plot of nonlinearity values, and the relationship between the dilution level and the measured value was determined to be linear.
[0084] Therefore, compared to the combination of reagent G and reagent K, which used catalase in the first step and peroxidase in the second step (Figure 5: Comparison Example 5), it was confirmed that the linearity was improved in the combinations of reagent H and reagent L (Figure 6: Example 13), reagent I and reagent L (Figure 7: Example 14), and reagent J and reagent L (Figure 8: Example 15), which used peroxidase in the first step.
[0085] Examples 16 to 18, Comparative Example 6 The reagent composition used in the first step was designated as the first reagent, and the reagent composition used in the second step was designated as the second reagent. The above reagents M to P were used as the first reagent, and the above reagents Q to R were used as the second reagent, and linearity was evaluated.
[0086] 150 μL of the first reagent was added to 2 μL of sample and reacted at 37°C for 5 minutes, after which 50 μL of the second reagent was added and reacted for 5 minutes. The absorbance at a main wavelength of 600 nm and a sub wavelength of 700 nm was measured, and the sdLDL cholesterol concentration in the sample was measured based on a previously prepared calibration curve. A sample with a high concentration of sdLDL was diluted in 10 steps so that the ratio of the sample to physiological saline was 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0, and the measured values were evaluated for linearity in accordance with the CLSI guideline EP-06A in the same manner as in Examples 10 to 12 and Comparative Example 4. The results of the combination of Reagent M and Reagent Q (Comparative Example 6), the combination of Reagent N and Reagent R (Example 16), the combination of Reagent O and Reagent R (Example 17), and the combination of Reagent P and Reagent R (Example 18) are shown in Figures 9, 10, 11, and 12, respectively. In Figure 9 (Comparative Example 6), the difference plot of nonlinearity values at each dilution level are significantly above and below zero, indicating that the straight line is significantly distorted. On the other hand, in FIG. 10 (Example 16) to FIG. 12 (Example 18), linear regression is selected for the difference plot of nonlinearity, and the relationship between the dilution level and the measurement value is determined to be linear.
[0087] Therefore, compared to the combination of reagents M and Q (Figure 9: Comparative Example 6), which used catalase in the first step and peroxidase in the second step, it was confirmed that the linearity was improved in the combinations of reagents N and R (Figure 10: Example 16), reagents O and R (Figure 11: Example 17), and reagents P and R (Figure 12: Example 18), which used peroxidase in the first step.
Claims
1. A method for quantifying HDL cholesterol, comprising a first step of transferring lipoprotein cholesterol other than HDL cholesterol in a diluted test sample to outside a reaction system, and a second step of quantifying HDL cholesterol remaining in the reaction system, The concentration of HDL cholesterol in the diluted test sample to be subjected to the first step is 19.1 mg / dL or less; A method for suppressing a decrease in the measured value of HDL cholesterol by making 1.2 U / mL or more of peroxidase present in the first step.
2. The method according to claim 1, wherein the dilution is from 2 to 40 times.
3. The method according to claim 1 or 2, wherein 1.2 to 50.0 U / mL of peroxidase is present in the first step.
4. The method according to any one of claims 1 to 3, wherein the concentration of HDL cholesterol in the diluted test sample subjected to the first step is 2.2 to 7.8 mg / dL.
5. A kit for quantifying HDL cholesterol used in any one of the methods of claims 1 to 4, comprising a first reagent for transferring lipoprotein cholesterol other than HDL cholesterol out of a reaction system, and a second reagent for quantifying HDL cholesterol remaining in the reaction system, the first reagent comprising 1.2 U / mL or more of peroxidase.
Citation Information
Patent Citations
Determination of cholesterol in lipoprotein fraction having high specific gravity and determination reagent kit
JP1997000299A
Determination of cholesterol and reagent therefor
JP1999018798A
Method and reagent for measuring lipoprotein cholesterol
JP2000325097A
Determination of cholesterol in high density lipoprotein
JP2001095600A
Fixed-amount reagent of small particle specific gravity lipoprotein
JP2013148589A
